| 1. |
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin, 2015, 65(1): 5-29.
|
| 2. |
Bockhorn M, Uzunoglu FG, Adham M, et al. Borderline resectable pancreatic cancer: a consensus statement by the International Study Group of Pancreatic Surgery (ISGPS). Surgery, 2014, 155(6): 977-988.
|
| 3. |
Vincent A, Herman J, Schulick R, et al. Pancreatic cancer. Lancet, 2011, 378(9791): 607-620.
|
| 4. |
Gillen S, Schuster T, Meyer Zum Büschenfelde C, et al. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med, 2010, 7(4): e1000267.
|
| 5. |
Youngwirth LM, Nussbaum DP, Thomas S, et al. Nationwide trends and outcomes associated with neoadjuvant therapy in pancreatic cancer: an analysis of 18?243 patients. J Surg Oncol, 2017, [Epub ahead of print].
|
| 6. |
Heinrich S, Pestalozzi BC, Sch?fer M, et al. Prospective phaseⅡtrial of neoadjuvant chemotherapy with gemcitabine and cisplatin for resectable adenocarcinoma of the pancreatic head. J Clin Oncol, 2008, 26(15): 2526-2531.
|
| 7. |
Sahora K, Kuehrer I, Schindl M, et al. NeoGemTax: gemcitabine and docetaxel as neoadjuvant treatment for locally advanced nonmetastasized pancreatic cancer. World J Surg, 2011, 35(7): 1580-1589.
|
| 8. |
Motoi F, Ishida K, Fujishima F, et al. Neoadjuvant chemotherapy with gemcitabine and S-1 for resectable and borderline pancreatic ductal adenocarcinoma: results from a prospective multi-institutional phase 2 trial. Ann Surg Oncol, 2013, 20(12): 3794-3801.
|
| 9. |
Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med, 2011, 364(19): 1817-1825.
|
| 10. |
Stein SM, James ES, Deng Y, et al. Final analysis of a phaseⅡstudy of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer. Br J Cancer, 2016, 114(7): 737-743.
|
| 11. |
Mahaseth H, Brutcher E, Kauh J, et al. Modified FOLFIRINOX regimen with improved safety and maintained efficacy in pancreatic adenocarcinoma. Pancreas, 2013, 42(8): 1311-1315.
|
| 12. |
Kelly P, Das P, Pinnix CC, et al. Duodenal toxicity after fractionated chemoradiation for unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys, 2013, 85(3): e143-e149.
|
| 13. |
Chuong MD, Frakes JM, Figura N, et al. Histopathologic tumor response after induction chemotherapy and stereotactic body radiation therapy for borderline resectable pancreatic cancer. J Gastrointest Oncol, 2016, 7(2): 221-227.
|
| 14. |
Stokes JB, Nolan NJ, Stelow EB, et al. Preoperative capecitabine and concurrent radiation for borderline resectable pancreatic cancer. Ann Surg Oncol, 2011, 18(3): 619-627.
|
| 15. |
Katz MH, Shi Q, Ahmad SA, et al. Preoperative modified FOLFIRINOX treatment followed by capecitabine-based chemoradiation for borderline resectable pancreatic cancer: Alliance for Clinical Trials in Oncology Trial A021101. JAMA Surg, 2016, 151(8): e161137.
|
| 16. |
Katz MH, Pisters PW, Evans DB, et al. Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg, 2008, 206(5): 833-846.
|
| 17. |
Speicher MR , Pantel K. Tumor signatures in the blood. Nat Biotechnol, 2014, 32(5): 441-443.
|
| 18. |
Sausen M, Phallen J, Adleff V, et al. Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients. Nat Commun, 2015, 6: 7686.
|
1/5
WeChat